Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.
about
Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Analyses of anticancer drugs by capillary electrophoresis: a review.Gene transfection in high serum levels: case studies with new cholesterol based cationic gemini lipids.Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediateSimultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-MethylselenocysteineAnti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and AlternativeEpirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo.Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)Development of multiple stimuli responsive magnetic polymer nanocontainers as efficient drug delivery systems.Protein nanocapsules containing doxorubicin as a pH-responsive delivery system.Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation.Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).Inhibition of transferrin iron release increases in vitro drug carrier efficacyGenetically engineering transferrin to improve its in vitro ability to deliver cytotoxins.
P2860
Q28829762-ED12832C-348D-4BA1-A443-93E0E18A5DB3Q33578254-7E0DFDEC-634F-46B8-A266-4FEBC935C4F5Q34811445-605D70D8-DE51-4F45-92D9-8270891DC1E5Q34827214-A89FC55E-1A9B-4DC8-B008-53725AE7E1E4Q35180943-871D139E-AAE8-4239-8A17-8B54CCBC67B5Q35222776-34787E8B-BD06-4B69-89BC-EC7D3A0C89F7Q35237773-17B0B652-46D6-4330-9F57-64C8E41943E5Q35892041-54DE0CC6-9B71-453C-871E-5A67CE0D8FA6Q35892045-3043B95C-43D5-4A6B-9C62-D2AA048C54DFQ35896698-3BFA5F03-A051-4B56-AE51-E98F6CFE770FQ36083695-AEC2B2FF-E3A5-42D3-AD7D-2807616778BAQ36311218-09D6F760-5FD2-4CAE-B71B-BD4A9012DFC9Q39084217-A951DEF2-B9ED-41F0-A904-34648B4DE41EQ39566545-7FC768E1-D014-4F44-80B1-F33AE88DD015Q39845394-9D75BAAF-D930-4BAF-948F-76E1E81E9118Q40205149-F463D785-2CCB-43C7-B192-16F58C005D50Q40649082-BE154BC7-BEC6-4E6F-8143-640E6A7EFD69Q40678981-47CD60B7-9860-4FA7-A7A8-C4FFA323015DQ41831883-F2A4FE18-43B8-4EEE-8E71-A7E00F41F17EQ42212432-0156E4BD-4C5D-40ED-876E-0A690F012397
P2860
Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Differences in the intracellul ...... shown by confocal microscopy.
@ast
Differences in the intracellul ...... shown by confocal microscopy.
@en
type
label
Differences in the intracellul ...... shown by confocal microscopy.
@ast
Differences in the intracellul ...... shown by confocal microscopy.
@en
prefLabel
Differences in the intracellul ...... shown by confocal microscopy.
@ast
Differences in the intracellul ...... shown by confocal microscopy.
@en
P2093
P356
P1476
Differences in the intracellul ...... shown by confocal microscopy.
@en
P2093
Rothern-Rutishauser B
Wunderli-Allenspach H
P356
10.1023/A:1011018525121
P577
2001-01-01T00:00:00Z